Maybe before I do that I should just say a good thank you to Mr. Wallace for handing off the technical explanations to me, drawing deeply on my five months of experience in the industry.
With respect to the ACR you mentioned—and I'm not talking based on first-hand knowledge, but more recounting what my colleagues have briefed me on—the machine that was being evaluated at that time was the ACR-700, as opposed to the ACR-1000. So it was indeed an earlier generation of the current product.
At that time, the NRC said there were no fundamental barriers to the licensability of the machine, but it was clear from a marketing point of view that we needed to make changes that would result in a power reactor, the ACR-1000, that had a negative PCR design. That is in fact the case today; the ACR-1000 is indeed designed to that basis.
The other thing I should point out, though, is that although these measures are cousins of each other, they are not the same. So the PCR coefficient and the way it's measured and applied and interpreted, as it relates to the MAPLE reactor, is not the same, and you can't draw a direct conclusion between one and the other.